Method of producing salts of s-adenosile-methionine derivatives

专利摘要:
New S-adenosylmethionine (SAM) salts of formula have been prepared in which: R is H, or a linear or branched aliphatic radical of 1-6 carbon atoms; R, is H, or a linear or branched aliphatic or aromatic acyl of 2-12 carbon atoms; R2 is H, or a linear or branched aliphatic or aromatic acyl of 2-12 carbon atoms; m is 0 or 1; n is 0-5; and A is the equivalent of an inorganic nr organic acid of pH less than 2.5, in which R1 can be the same as or different from R2, and at least one of the radicals R, R1, R2 is other than hydrogen. The methods of preparing the new products starting from SAM salts are described. The new products are stable and highly bioavailable, particularly when administered orally.
公开号:SU1340592A3
申请号:SU823494860
申请日:1982-09-10
公开日:1987-09-23
发明作者:Дженнари Федерико
申请人:Биорисерч С.П.А. (Фирма)；
IPC主号:

专利说明:

k
  A- n H A CD
1rjA0592
The invention relates to chemistry, bo-8-adeno, and chem. 5 (SAM) fOiiieu, specifically, to a method for the preparation of nominal compounds — salts of derivatives,
H-i
About s
N N
 he is OH 0
where R is linear or branched
an alkyl radical with 1-6 carbon atoms; A is the equivalent of an acid with a pKa of 2.5;
n 0-4.
The aim of the invention is to obtain new biologically active compounds with higher
sn.
)five
n
the mixture is filtered. Then the solution is titrated.
To obtain the molar ratio of the methyl ester of SAM and sulfuric acid 1: 2, a sufficient amount of concentrated sulfuric acid is added, and then the solution is lyophilized.
820 g of methyl complex are obtained.
stability and enhanced SAM ester capacity of 66.8% of the proposed formula to pass through cellular meme- (R CHj) H, 31.7%, HjO 1.5%, which corresponds to a yield of 54.7%.
Example 1. Amount of Sulfate When analyzed by high-performance SAM, corresponding to 1 kg (2.732 mol) in liquid chromatography (Partisil-10 SCX column, ammonium formic acid 0.1 M, pH A, 20% SAM meions, dissolved in 20 liters of methanol containing 4.6% by weight of concentrated sulfuric acid. The solution is heated under reflux for 16 hours, cooled and diluted with 20 liters of distilled water. The resulting solution is passed through Amberlite-IRA-93 column, previously activated with 2N NaOH and washed to pH 3. Use 15 liters of resin.
The eluate is filtered and washed with distilled water. The methanol is evaporated in vacuo. The resulting solution was boiled for 20 minutes to remove traces of unreacted SAM, and then cooled.
Prepare an Amberlite IRC-50 column in the H-form containing 40 liters of resin, activated with 100 liters of 0.5N. HjSO washed until neutral. The previously obtained solution is neutralized to a pH of 6.5. 2N. NaOH is passed through the column at a rate of 40 l / h, then washed with 40 l N, 0.
Through the column pass 0.1 n. Acetic acid solution to (about 200 l), and then let in 40 l of distilled water.
Elution was carried out with 60 L 0.1 N. . The eluate is concentrated in vacuo (30 mm Hg) to approximately 10 liters, 50 g of activated charcoal are added and the resulting
tanol, flow rate 1 ml / min) about 30
The product gives one live 580 s.
the peak with the UV back-spectrum time: pH 4, the absorption maximum at 258 nm is 14040J pH 1, .. the absorption maximum at 256 nm is f 13500.
35 NMR spectrum, ppm: 3 (singlet-CH5-groups), 3.7 (singlet of the R-C-O-CHj6 group).
If the ratio of methyl ester SAM and sulfuric acid is 1: 1.5 or 1: 2.5 (molecular ratio) is set before lyophilization, then the solution is lyophilized, the corresponding methyl salt is obtained.
45 SAME ester SAM 1,5 xO, 5 HjO, methyl ester, 5 X 0.5 H,; 0.
50
55
If the column IRC-50 is eluted instead of hydrochloric acid, the following salts are obtained: methyl ester SAM 3HC1-0.5, methyl ester, 5, methyl ester SA 1 5HC1 0.5.
Similarly, using methanesulfonic acid, the corresponding methanesulfonates are obtained,
Analytical data for these salts are given in table. one.
n
the mixture is filtered. Then the solution is titrated.
To obtain the molar ratio of the methyl ester of SAM and sulfuric acid 1: 2, a sufficient amount of concentrated sulfuric acid is added, and then the solution is lyophilized.
tanol, flow rate 1 ml / min) about 30
The product gives one live 580 s.
the peak with the UV back-spectrum time: pH 4, the absorption maximum at 258 nm is 14040J pH 1, .. the absorption maximum at 256 nm is f 13500.
35 NMR spectrum, ppm: 3 (singlet-CH5-groups), 3.7 (singlet of the R-C-O-CHj6 group).
If the ratio of methyl ester SAM and sulfuric acid is 1: 1.5 or 1: 2.5 (molecular ratio) is set before lyophilization, then the solution is lyophilized, the corresponding methyl salt is obtained.
45 SAME ester SAM 1,5 xO, 5 HjO, methyl ester, 5 X 0.5 H,; 0.
If the column IRC-50 is eluted instead of hydrochloric acid, hydrochloric acid is obtained, the following salts are obtained: methyl ester SAM 3HC1-0.5, methyl ester, 5, methyl ester SA 1 5HC1 0.5.
Similarly, using methanesulfonic acid, the corresponding methanesulfonates are obtained,
Analytical data for these salts are given in table. one.
EXAMPLE 2 Repeat the procedure described in Example 1, with the exception that the starting compounds were refluxed for 14 hours using absolute ethanol containing 4.6% by weight of sulfuric acid.
The ethyl ester SAM is obtained in the amount of 840 g as the ethyl ester SAM-2HjS (VO, 5 composition,%: SAM-ethyl ester (formula I, R - 67.6; HjSOt 31; 1.4.
the maximum absorbed is 14.040; pH 1, at 256 nm
0.9 (triplet.
UV spectrum: pH 4, maximum absorbed at 258 nm E «14040; pH 1, maximum absorption at 256 nm "13300.
NMR spectrum, MD 1.25 (triplet.
UV spectrum: pH 4, neither at 258 nm f the absorption maximum is B 13,500.
NMR spectrum, ppm
characteristic of the R-CHj group); 3 (singlet characteristic of an 8-CH5 group), 4.1 (quadruplet characteristic of a 10 C – C – CH – K group).
ABOUT
When analyzed by high performance liquid chromatography under the conditions of Example 1, the product gives one peak, a retention time of 650 seconds.
Under the conditions described, a series of salts are obtained, similar to those shown in examples 1 and 2.
Using n-pentanol and n-hexanol
R-CH, -groups); 3 (singlet, S-CHj groups); 20 instead of butanol get n-pentyl
, 4.2 (quadruplet of the C – C – O – CH – H group).
O Yield 55%.
When examined by high performance liquid chromatography under the conditions of Example 1, the product gives one peak with a retention time of 600 s.
According to the method described in example 1, it is possible to obtain a whole range of salts: ethyl ester SAM x X 1j5 HjSO g 0.5 HjOj ethyl ester SAM 2.5 HiS04 0.5, ethyl ester, 5, ethyl ester BAM -4 HCl x .c 0.5 ethyl ester SAM 5 HCl.0.5 HjO; ethyl ester ZAM DECISION “0.5 HjO; ethyl ester СНз50зН 0.5 ethyl ester 8АМ 5СНз80 | Н x X 0.5 Hjp.
The UV and NMR spectra of all these salts are identical to the spectra of the previously mentioned salts.
EXAMPLE 3: The procedure described in Example 1 is repeated using n-butanol containing 4.6% by weight of sulfuric acid and heating the initial mixture under reflux for 10 hours.
V
First, a suspension is obtained which turns into a more transparent solution after refluxing.
 a mixture of SAM n-butyl ester of the following formula: SAM 2 H. X 0.5 HjO n-butyl ester.
35
and n-hexyl esters.
In tab. 2 provides analytical data for esters .SAM, obtained in examples 2 and 3.
25
Example 4 A quantity of SAM sulphate, equivalent to 1 kg of SAM ions, is dissolved in 20 liters of isopropyl alcohol containing 2Z (by volume) of concentrated sulfuric acid. The solution is heated for 16 hours. The resulting reaction mixture is treated with Amberlite resin, as in Example 1. SAMi 2H2SOx-X 0.5 HjO 855 g isopropyl ester is obtained, composition,%: SAM 68, isopropyl ester; sulfuric acid 30; 55; water 1.45.
PRI me R 5. The amount of sulfate ZAM, corresponding to 1 kg of SAM ions,
40 is dissolved in 20 liters of isobutyl alcohol containing 2% (by volume) concentrated sulfuric acid. The solution is heated under reflux for 16 hours. The resulting reaction mixture
45 is treated with Amberlite resin as in Example 1. Isobutyl ester is obtained SAM 2 H2SO4 0.5 860 g, composition, isobutyl ester
SAM, 68.5; sulfuric acid 30.1; water 1.4.
The stability of the obtained salts of esters of derivatives of S-adenosylmethionine is compared with the stability of the salt of S-adenosylmethionine.
In tab. 3 shows the stability of aqueous solutions of salts of SAM esters (p 3) at different pH.
the pH of aqueous solutions set by adding a certain amount
50
55
the maximum absorbed is 14.040; pH 1, at 256 nm
0.9 (triplet.
15
40592
UV spectrum: pH 4, neither at 258 nm f the absorption maximum is B 13,500.
NMR spectrum, ppm
characteristic of the R-CHj group); 3 (singlet characteristic of an 8-CH5 group), 4.1 (quadruplet characteristic of a 10 C – C – CH – K group).
ABOUT
When analyzed by high performance liquid chromatography under the conditions of Example 1, the product gives one peak, a retention time of 650 seconds.
Under the conditions described, a series of salts are obtained, similar to those shown in examples 1 and 2.
Using n-pentanol and n-hexanol
20 instead of butanol get n-pentyl
five
and n-hexyl esters.
In tab. 2 provides analytical data for esters .SAM, obtained in examples 2 and 3.
five
EXAMPLE 4 A SAM sulphate equivalent to 1 kg SAM ions is dissolved in 20 liters of isopropyl alcohol containing 2Z (by volume) concentrated sulfuric acid. The solution is heated for 16 hours. The resulting reaction mixture is treated with Amberlite resin, as in Example 1. SAMi 2H2SOx-X 0.5 HjO 855 g isopropyl ester is obtained, composition,%: SAM 68, isopropyl ester; sulfuric acid 30; 55; water 1.45.
PRI me R 5. The amount of sulfate ZAM, corresponding to 1 kg of SAM ions,
0 is dissolved in 20 liters of isobutyl alcohol containing 2% (by volume) concentrated sulfuric acid. The solution is heated under reflux for 16 hours. The resulting reaction mixture
5 treated with resin Amberlite as in example 1. Get isobutyl ester SAM 2 H2SO4 0.5 860 g, composition, isobutyl ether
SAM, 68.5; sulfuric acid 30.1; water 1.4.
The stability of the obtained salts of esters of derivatives of S-adenosylmethionine is compared with the stability of the salt of S-adenosylmethionine.
In tab. 3 shows the stability of aqueous solutions of salts of SAM esters (p 3) at different pH.
the pH of aqueous solutions set by adding a certain amount
0
five
The obtained results demonstrate a higher stability of the salts of the SAM esters compared to the SAM. The ability of the salts of SAM esters to pass through cell barriers is characterized by the data given and Table. four.
 In the in situ experiment (intestinal sacs), 2 mg of each test product in 1 ml of saline is placed in the intestinal sacs of the rats under ether anesthesia. The rats die after 2 hours and the residual content of the sac (wall + content) is analyzed. The amount of product migrated thus determined is given in t abl. 4 (%) of the initial amount in the bag.
In other experiments, Q pieces were used for the treatment of hepatitis stevirus gut that was kept at 37 ° C (according to the Krebs-Rinder method) in a solution with an external concentration of the test compound 10 M.
The amount of absorbed product, confirmed by analysis, is given in table. 4 in the form of specific vetozakh, caused by hyperlipid-hyperbelk diet according to the method of Handler, and in case of steatosis, caused by acute alcohol poisoning and other
25
faces, i.e. mol / h / mg tissue. Salts of all compounds are obtained with the same amount.
Compounds (I) are well absorbed in the intestinal tract, and more intensively than SAM sulphate, which makes it possible to achieve in oral plasma significantly higher concentrations of the active substance than when using SAM sulphate.
Toxicity. Acute toxicity is determined in mice. In all, the following values are obtained: LD for oral treatment more than 3 g / kg, for intravenous administration more than 1 kg. I
The tolerability and chronic toxicity tests were carried out on Wistar and Sprague-Dowley rats, and they were administered 20 mg / kg per day of the test compound for 12 months. At the end of treatment, no pathological abnormalities were detected in various organs and systems.
Teratogenesis tests are performed on rabbits. With the introduction of doses of salts that are 10 times higher than the therapeutic maximum dose, no topographic effect or malignant tumors were observed on the embryos or grown fruits.
doses of 10 mg / kg SAM.
In experimental hyperlipemia in rats, for example, caused by Tritons, compound (I) demonstrated 30 extremely noticeable hypolipemic activity, which, at doses of 10 mg / kg (SAM ions), was significantly superior to other drugs with hypolipemic activity.
In chickens with atherosclerosis caused by a diet enriched with cholesterol and fructose, with parenteral administration of compounds (I) at doses of 10 mg / kg, cholesterol decreased and cases of damage were favorably modified compared to controls. thoracic and abdominal aorta and small vessels of the encephalic base.
35
45
50
As regards phospholipid metabolism, it was experimentally found that there is an increase in phosphatidylcholine in rat hepatitis tissue with uncompensated steatosis. A clear increase in phosphatidylcholine was also determined in hematical-lipoprotein experiments in experimental alterations caused by the C / O-lipoprotein ratios.
In all of these tests, there are clear indications of the therapeutic effect of compounds (I) in disorders of lipid metabolism.
With intravenous doses up to 200 mg / kg, pyrogenic effects were not found in rabbits.
When administered intravenously to rabbits and rats of 40 mg / kg, there were no changes in carotid pressure, heart rate and respiratory rate, or on the electrocardiogram. -Local tolerability of intramuscular injections, even after repeating infusions; for 30–60 days and intravenous injections into the marginal vein of the outer ear of rabbits was excellent.
Pharmacologists. A complete series of tests carried out on rats demonstrated that compounds (I) possess very noticeable defensiveness and resolvations caused by a hyperlipid-hyperbelly diet according to the Handler method, and in case of steatosis caused by acute alcohol poisoning and other diseases.
five
0
As regards phospholipid metabolism, it was experimentally found that there is an increase in phosphatidylcholine in rat hepatitis tissue with uncompensated steatosis. A clear increase in phosphatidylcholine was also determined in hematical-lipoprotein experiments in experimental alterations caused by the C / O-lipoprotein ratios.
In all of these tests, there are clear indications of the therapeutic effect of compounds (I) in disorders of lipid metabolism.
The next series of tests was performed.
on rats and she demonstrated
that doses of 1 mg / kg cause
accumulation of glycogenic reserves at the hepatitis and muscular levels, which is demonstrated both by histochemical methods and quantitative measurements. In the experimental diabetes caused by alloxan, the amount of anal activity of the compounds in the insulin necessary for returning (I) was carried out according to the method of Winter to reduce the glycemic values to normal, with the introduction of 0.5 mg / kg.
This series of experiments demonstrates 15 stinks (the method of Janssen and Yacheno). stride a clear positive
the effect of compound (I) on glucidic SAM sulfate, when orally administered, did not have any anti-inflammatory and analgesic active-hypo-disproteinemia, was treated with a prostrate. In addition, SAM anti-inflammatory agents at a dose of 10 mg / kg. It was discovered and analgesic activity that these products were used for the compounds (I) for disorders of proteolytic metabolism.
Compounds (I) also have significant anti-inflammatory and analgesic activity compared with the known.
Test anti-inflammatory and
Evaluation of their effect on edema caused by carragenin in rats, and reactions to burns in humans with hot plametabolism.
Rats with experimentally induced
The tensions (I) are higher than the corresponding SAM sulphate activity during intramuscular use.
rotates the total proteinaceous values to normal with a significant increase in albumin level and thus show a marked protein anabolic activity.
These and other similar tests have demonstrated therapeutic efficacy25
The tensions (I) are higher than the activity of sulfate SA by the long-term use.

权利要求:
Claims (1)
[1]
Formula isob
The method of obtaining from 8-adenosylmethionine
N42 N V- N
C.D. j)
Ij n
CH -S-CHiCH CHA-tiUA
OH
The channel of the genetic activity of compounds (I) was carried out according to the method of Winter,
the availability of compounds (I) in case of disorders of the protable metabolism.
Compounds (I) also have significant anti-inflammatory and analgesic activity compared with the known.
Test anti-inflammatory and
analgesic activity of compounds (I) was carried out according to the method of winter
However, assessments of their effect on edema caused by carragenin in rats and reactions to burns with hot sprays on hot SAM plastate when administered orally did not have any anti-inflammatory and analgesic activity. In addition, anti-inflammatory and analgesic activity of the compounds
The tensions (I) are higher than the corresponding SAM sulphate activity during intramuscular use.
Formula invented and
The method of obtaining salts of 8-adenosylmethionine derivatives of the general formula
where R is linear or branched
 -alkyl-, A - equivalent of acid with pKa
2.5v p 0-4,
characterized in that the salt solution of S-adenosylmethionine in the corresponding ROH alcohol, where R is refluxed, the resulting product is purified by passing the reaction mixture through a column with ion-exchange resin in H-form, eluted with dilute aqueous solution of acid HA, and after the eluate the concentration is added in an amount of HA.
necessary to achieve a given
While a certain amount of pn, 45 of p, the resulting salt, containing 1-3% concentrated S-adenosylmethionine, is extracted in volume, it is boiled with refluxing of sulfuric acid.
under reflux, the resulting product is purified by passing the reaction mixture through an H-form ion-exchange resin, eluted with a dilute aqueous solution of acid HA, and acid HA is added in an amount to the eluate after concentration.




14.79 14.78 14.08 14.01 247
13.61 13.73 15.56, 15.61 228
16.82 16.72 211
6.04 6.01 265
5.64 5.65
248
5.31 5.29, 233
11.85 11.87 18.05 17.99 198
10.48 10.49 19.88 19.86 174
9.32 9.29 21.31 21.35156
 Absorption is the ability of a 1% aqueous solution of compound (I) 1 cm thick at pH 4 in UV Light.
Table 2
SAM ethyl complex
ether 2HjSO -0.5
SAM n-propyl
ester 2HjSO X
X 0.5 HjO
Table 1
14.01 247
15.61 228
16.72 211
6.01 265
5.65
248
5.29, 233
17.99 198
19.86 174
21,35156
54.7 54.7
54.7 55.6 55.6 55.6
54.3 54.3 54.3
13.27 15.19 15.18 222 49.5
13.02 14.86 14.85 217 46.3
SAM n-butyl ester X X 0.5 HjO
SAM n-pentyl ester 2H2 SO4 X X 0.5 N, 0
SAM n-hexyl ester 2HjS04 X X 0.5 HjO
Continuation of table 2
14.55 14.52 213 41.1
 14.25 208 38.4
13.95 13.93 204 35.3
13
1340592
Table
U
Table3

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU1340592A3|1987-09-23|Method of producing salts of s-adenosile-methionine derivatives

---

EP2610242A1|2013-07-03|Positively charged water-soluble prodrugs of aspirin

---

US9969695B2|2018-05-15|N-substituted imidazole carboxylic ester chiral compound containing an ether side chain, its preparation and application

---

US5126373A|1992-06-30|Composition for parenteral and oral nutrition

---

EP0072980A1|1983-03-02|Stable S-adenosylmethionine salts, the process for their preparation and therapeutic compositions which contain them as active principle

---

CZ286621B6|2000-05-17|Tromethamine salt of |-|-2-|propionic acid, process of its preparation and pharmaceutical preparation containing thereof

---

BRPI0715084A2|2013-03-12|4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphan-3-aminobutyrate derivatives as cpt inhibitors

---

FI72525C|1987-06-08|FOERFARANDE FOER FRAMSTAELLNING AV TERAPEUTISKT ANVAENDBARA STABILA S-ADENOCYLMETIONINSALTER.

---

EP0346882A2|1989-12-20|Hydroxyalkylcysteine derivative and expectorant containing the same

---

CH664561A5|1988-03-15|ESTER OF ACETYL CARNITINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT.

---

US4784992A|1988-11-15|Phosphorylalkanolamide derivatives of L-carnitine and pharmaceutical compositions containing same

---

EP0207436B1|1991-04-03|New cytidine-diphosphocholine salts, particularly suitable for oral use

---

US5246967A|1993-09-21|Use of esters of acyl l-carnitines with gamma-hydroxybutyric acid for producing pharmaceutical compositions for the treatment of hepatopathies

---

WO2016110822A1|2016-07-14|Carboxylic biacyl creatine derivative, uses and method of synthesis thereof

---

KR880002433B1|1988-11-12|Process for the preparation of ascocloline derivation

---

US3002978A|1961-10-03|Glyceryl pyrrolidone carboxylates

---

US4897398A|1990-01-30|Hydrochlorides of chlorides of 2-aminoalkyl-9-hydroxy-ellipticinium derivatives and pharmaceutical compositions containing them

---

US4562206A|1985-12-31|Orally effective inotropic compounds

---

US3982002A|1976-09-21|Vincamine 2-ketoglutarate and compositions containing vincamine 2-ketoglutarate

---

US4288441A|1981-09-08|Nicotinoyl pantetheine derivatives

---

Zutshi et al.1990|Kinetic fate of potassium embelate, a non-narcotic centrally acting analgesic after oral and intravenous administration

---

CN111718352A|2020-09-29|Novel compound and pharmaceutically acceptable salt thereof

---

FI62283C|1982-12-10|FRAMEWORK FOR THE PREPARATION OF THERAPEUTIC NUTRITIONAL N-2'-CARBOXYPHENYL-4-CHLORANTRANYL SYRADERIVAT

---

CN1511840A|2004-07-14|Puerarin compound containing water soluble group and its preparation and use

---

JPH0723366B2|1995-03-15|Novel furan compound and method for producing the same

同族专利:

---

公开号 | 公开日

---

JPH0149276B2|1989-10-24|

---

DK405382A|1983-03-12|

---

CS241123B2|1986-03-13|

---

YU43092B|1989-02-28|

---

IL66713D0|1982-12-31|

---

ZA826408B|1983-07-27|

---

ES8403494A1|1984-04-01|

---

GR76720B|1984-08-29|

---

NZ201824A|1986-05-09|

---

DE3265425D1|1985-09-19|

---

MX5670A|1994-01-31|

---

IT8123940D0|1981-09-11|

---

NO153397B|1985-12-02|

---

PT75516A|1982-10-01|

---

FI74290C|1988-01-11|

---

ES515613A0|1984-04-01|

---

PT75516B|1985-07-26|

---

NO153397C|1986-03-12|

---

RU2041235C1|1995-08-09|

---

AT14884T|1985-08-15|

---

EP0074555A1|1983-03-23|

---

NO823088L|1983-03-14|

---

RO85286B|1984-10-30|

---

DK155332B|1989-03-28|

---

FI823142L|1983-03-12|

---

CS656082A2|1985-07-16|

---

YU204682A|1985-06-30|

---

DK155332C|1989-08-14|

---

CA1213886A|1986-11-12|

---

IL66713A|1987-08-31|

---

DK149957C|1987-06-15|

---

AU564577B2|1987-08-20|

---

RO85286A|1984-09-29|

---

PL141706B1|1987-08-31|

---

AU8813582A|1983-03-17|

---

PL238201A1|1983-05-09|

---

DK349085A|1985-08-01|

---

DK349085D0|1985-08-01|

---

JPS5857397A|1983-04-05|

---

HU186117B|1985-06-28|

---

FI74290B|1987-09-30|

---

DK149957B|1986-11-03|

---

EP0074555B1|1985-08-14|

---

IT1139974B|1986-09-24|

---

FI823142A0|1982-09-10|

---

US4558122A|1985-12-10|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US2969353A|1957-02-06|1961-01-24|Merck & Co Inc|Process for the preparation of "active methionine" and products obtained thereby|

---

DE1803978C2|1968-10-18|1985-05-02|Boehringer Mannheim Gmbh, 6800 Mannheim|Process for the production of S-adenosyl-l-methionine and S-adenosyl-l-ethionine|

---

IE37913B1|1972-08-02|1977-11-09|Bioresearch Sas|Salt of s-adenosyl-l-methionine|

---

US4028183A|1973-06-27|1977-06-07|Bioresearch Limited|Process of preparing double salts of S-adenosyl-L-methionine|

---

IE39517B1|1973-06-27|1978-10-25|Bioresearch Sas|Double salts of s-adenosyl-l-methhionine|

---

JPS5320998B2|1974-06-13|1978-06-29|

---

FR2275220B1|1974-06-21|1978-07-28|Merieux Inst|

---

AR221676A1|1974-07-12|1981-03-13|Bioresearch Sas|PROCEDURE FOR THE PREPARATION OF SULPHONIC AND / OR SULFURIC STABLE SALTS OF S-ADENOSIL-L-METIONINE, PARTICULARLY USEFUL AS SPECIFIC METHYL DONORS FOR THE CH3, ELAMIBLI-TRANSFERRING BIOCHEMICAL AND LATIN-GLOBAL ELEMENTS PROTILICO AND GLUCIDICO|

---

GB2001976B|1977-08-03|1982-03-10|Yamasa Shoyu Kk|S-adenosyl-l-methionine compositions and production thereof|

---

GB2064523B|1979-12-04|1983-06-29|Kanegafuchi Chemical Ind|Stable composition of s-adenosyl-l-methionine|

---

JPS5699499A|1980-01-10|1981-08-10|Kanegafuchi Chem Ind Co Ltd|Composition containing s-adenosyl-l-methionine, and its preparation|

---

JPS56145299A|1980-04-11|1981-11-11|Kanegafuchi Chem Ind Co Ltd|Purification of s-adenosyl-l-methionine|

---

JPS57156500A|1981-03-23|1982-09-27|Kanegafuchi Chem Ind Co Ltd|Composition containing s-adenosyl-l-methionine and its preparation|IT1169773B|1983-08-24|1987-06-03|Bioresearch Spa|PROCESS FOR THE PRODUCTION OF STABLE SALTS OF SULPHO-ADENOSYL-L-METHIONINE|

---

CA1291092C|1988-03-11|1991-10-22|Donald A. Poole|Easy opening gable top carton|

---

IT1229514B|1989-01-30|1991-09-03|Farmhispania S A A Montme|SYNTHETIC AMPHIPHILIC GLYCOCONUGATES FOR NEUROLOGICAL USE.|

---

JPH02290896A|1989-04-28|1990-11-30|Fuji Kagaku Kogyo Kk|Novel s-adenosylmethionine derivative|

---

US5180714A|1990-10-31|1993-01-19|Health Research, Inc.|Adenosine compounds for the treatment of diseases caused by parasitic protozoa|

---

US8642581B1|2000-02-11|2014-02-04|Brian D. Halevie-Goldman|Compositions and methods for the production of S-adenosylmethionine within the body|

---

US6649753B2|2001-06-07|2003-11-18|Orchid Chemicals & Pharmaceuticals Ltd.|Stable salts of S-adenosyl-L-methionineand the process for their preparation|

---

US20040116351A1|2002-12-06|2004-06-17|Fast Balance, Inc.|Method for enhancing the natural reward system for exercise|

---

US20050272687A1|2004-06-08|2005-12-08|Hebert Rolland F|Stable S-adenosyl-l-methionine|

---

US20090012036A1|2005-05-24|2009-01-08|Hebert Rolland F|Stable S-adenosyl-L-methionine|

---

ITMI20060629A1|2006-03-31|2007-10-01|Daniele Giovannone|ORAL SOLID COMPOSITIONS BASED ON S-ADENOSYLMETIONINE AND PROCESS FOR THEIR ACHIEVEMENT|

---

JP2008013509A|2006-07-07|2008-01-24|Fujifilm Corp|Method for preserving s-adenosylmethionine|

---

ITMI20071374A1|2007-07-10|2009-01-11|Gnosis Spa|STABLE STABLE OF S-ADENOSYLMETHIONINE AND PROCESS FOR THEIR ACHIEVEMENT.|

---

US20100004191A1|2008-07-01|2010-01-07|Rolland F Hebert|Compositions of S-adenosyl-L-methionine.|

---

WO2012016704A1|2010-08-05|2012-02-09|Cellzome Ag|Methods for the identification of methyltransferase interacting molecules and for the purification of methyltransferase proteins|

---

KR102186066B1|2013-01-16|2020-12-04|허버트 샘-이 엘엘씨|Stable indole-3-propionate salts of s-adenosyl-l-methionine|

---

WO2015028927A1|2013-08-25|2015-03-05|Mahesh Kandula|Compositions and methods for the treatment of metabolic diseases|

---

TR201807235T4|2015-10-05|2018-06-21|Tetra Laval Holdings & Finance|An application unit for applying a lid onto a container.|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

IT23940/81A|IT1139974B|1981-09-11|1981-09-11|DERIVATIVES OF S-ADENOSYLMETHIONINE, PROCESS FOR PREPARATION AND THERAPEUTIC COMPOSITIONS THAT CONTAIN THEM AS AN ACTIVE INGREDIENT|

---